About the Authors
- Nasheed Moqueet
-
Affiliation Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada
- Cynthia Kanagaratham
-
Affiliation Department of Medicine and Department of Human Genetics, McGill University, Montreal, QC, Canada
- M. John Gill
-
Affiliation Southern Alberta HIV Clinic, Calgary, Alberta, Canada
- Mark Hull
-
Affiliation BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada
- Sharon Walmsley
-
Affiliation Toronto General Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada
- Danuta Radzioch
-
Affiliation Department of Medicine and Department of Human Genetics, McGill University, Montreal, QC, Canada
- Sahar Saeed
-
Affiliation Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada
- Robert W. Platt
-
Affiliation Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada
- Marina B. Klein
-
* E-mail: marina.klein@mcgill.ca
Affiliations Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada
- for the Canadian Co-infection Cohort Study (CTN 222)
-
¶Membership of the Canadian Co-infection Cohort Study (CTN 222) is provided in the Acknowledgments
Competing Interests
The authors of this manuscript have the following competing interests: MBK received research grants for investigator initiated trials from Merck and ViiV Healthcare; consulting fees from ViiV Healthcare, Bristol-Meyers Squibb, Merck, Gilead and AbbVie. JG received personal fees for being a member of the national advisory boards of Abbvie, Gilead, Merck, Janssen, and ViiV Healthcare. MH reports honoria for advisory boards and speaker's engagements from Abbie, Bristol-Myers Squibb, Gilead, Merck, Ortho-Janssen, and ViiV Healthcare. SW received grants, consulting fees, lecture fees, nonfinancial support and fees for the development of educational presentations from Merck, ViiV Healthcare, GlaxoSmithKline, Pfizer, Gilead, Abbvie, Bristol-Myers Squibb and Janssen. RP reports personal fees from Amgen, Abbvie, Pfizer, and Novartis. No conflict of interests were declared by the other authors. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: NM MBK RWP. Data curation: CK DR NM. Formal analysis: NM RWP MBK CK. Funding acquisition: MBK. Investigation: NM CK. Methodology: NM RWP MBK. Project administration: NM SS. Resources: CK DR MBK MJG MH SW CTN222. Supervision: MBK RWP DR. Validation: CK DR. Visualization: NM. Writing – original draft: NM MBK. Writing – review & editing: NM CK DR MJG MH SW SS RWP MBK.